The Food and Drug Administration and the Defense Department have formalized the framework of an earlier plan to accelerate the development and availability of emergency medical products for the U.S. military.
FDA said Friday it signed a memorandum of understanding with the DoD’s Office of Health Affairs to commence with the program’s implementation, as provided for under House Resolution 4374 that was passed in 2017.
The MoU authorizes the FDA and the Pentagon to work toward faster deployment of medical products meant to diagnose, treat or prevent life-threatening conditions affecting U.S. service members, including those caused by chemical, biological, radiological or nuclear agents.
“It’s our honor and duty to support our military personnel by ensuring they have access to safe and effective medical products – especially products that meet the unique needs and settings in which soldiers may require medical treatment,” said FDA Commissioner Scott Gottlieb.
Â
